Join
Live feed
·
PRReleasevia Quantisnow
Moleculin Biotech Inc. logo

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

ByQuantisnow·Wall Street's wire, on your screen.
MBRX· Moleculin Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MBRX (Moleculin Biotech Inc.) and more on Quantisnow.